A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Blood Cancer
-
Age: Between 12 Year(s) - 80 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Morphologic and immunophenotypic evidence of CD19+ disease in peripheral blood or bone marrow as assessed by flow cytometry
- Have received at least 2 prior lines of therapy to which the participant has been either refractory or has subsequently relapsed OR have received one prior line of therapy to which the participant has been either refractory or has subsequently relapsed and the participant is not eligible or has no other available standard treatment options
- Prior TCE > 4 weeks, prior CAR-T cell therapy or autologous SCT > 8 weeks, or prior alloSCT > 12 weeks, and who do not require immunosuppressive therapy for the treatment of acute or chronic GVHD within 3 weeks prior to AZD0486 treatment
You may not be eligible for this study if the following are true:
-
- Isolated extramedullary disease relapse
- Participants with Burkitt’s lymphoma/leukaemia
- Active CNS involvement by ALL
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.